Altair Medical

As 2020 draws to a close, Dr Bruce Henderson (CEO) reviews the major advances and developments at Altair Medical during the year.

As Covid 19 has accelerated the adoption of Digital Health technology, Altair’s AI driven remote respiratory monitoring platform has proven to be of enormous interest to a large number of healthcare providers and commercial partners as we all seek to address the needs of respiratory patients currently unmet by existing technology.

Even before the pandemic, market pull had broadened our product focus to embrace all respiratory illness, rather than the previous focus on opioid related monitoring, and this has opened up a range of opportunities.

Our key successes in 2020 include:

  • After 3 years of laboratory-based R&D, our first clinical trials started in NHS hospitals in October 2020;
  • The ease of use of our platform has exceeded the expectations of the NHS R&D team and allowed 1,000s of hours of clinical data to be collected and analysed from more than 50 patients to date with severe respiratory illness;
  • This rate of data capture is generating rapid algorithm development and validation, delivering compelling early insights on novel digital biomarkers;
  • Our data platform is already infinitely scalable following Integration with Galen Data’s secure medical device cloud platform (www.galendata.com);
  • A range of clinical trials will continue throughout 2021 and beyond. As well as expanding NHS clinical trials into new patient groups in healthcare facilities and at home, we are collaborating with a leading Scottish University to develop breakthrough insights on the efficacy of inhaled medications.

In addition, we have:

  • Patent applications near completion in the US and UK;
  • Invoiced first commercial revenues; and
  • Engaged with a wide range of financial and strategic investors.

All of this brings us closer to regulatory approval via the Breakthrough Device Program awarded to Altair by the US FDA – a program for innovative, life-saving medical technology that offers substantial advantages over existing approved or cleared devices. As well as priority review for regulatory clearance, the program offers rapid US insurer approval and access to our primary market in advance of global expansion.

The range and diversity of unmet needs that our technology has the potential to address is generating a momentum to the business that is exciting to be a part of. I hope you agree that 2020 has been a great year for us, but there is plenty to work on in 2021.

If you would like to hear more on any of these points, please do not hesitate to get in touch.
Enjoy the holiday season and I hope to speak to you in the New Year.

Dr Bruce Henderson
CEO
Altair Medical Limited